Pulmonx (LUNG) Earnings Date & Reports

Key Takeaways

• Pulmonx reported third quarter 2026 revenue of $22.8 million, up 6% year over year and above the consensus estimate of $21.93 million.
• Net loss narrowed 40% to $8.4 million, or $0.19 per share, beating the consensus expectation of a $0.26 per-share loss.
• Gross margin improved to 76%, and management raised its full-year 2026 gross margin outlook to approximately 77%.
• Operating expenses fell 18% to $24.9 million, underscoring the company's cost-reduction efforts.
• Management reiterated full-year 2026 revenue guidance of $90 million to $92 million.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss narrowed nearly 60% to $3.5 million.
• For more context on this ticker, you can explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• You can also discover related trading strategies by exploring Trending AI Robots.

Earnings Context and Why It Matters

Pulmonx Corporation (NASDAQ: LUNG) is a medical technology company focused on minimally invasive treatments for chronic obstructive pulmonary disease (COPD), a progressive lung condition. Its flagship Zephyr Endobronchial Valve treats patients with severe emphysema. The third quarter of 2026 marked a pivotal moment: the company returned to year-over-year revenue growth in both its U.S. and international businesses for the first time since its current leadership team rejoined the company. Coming after a period of commercial reset, this report offers investors a key signal on whether Pulmonx's rebuilt sales organization and cost discipline can translate into sustained top-line expansion and a clearer path toward profitability.

Reported Results

Pulmonx reported total worldwide revenue of $22.8 million for the third quarter ended September 30, 2026, a 6% increase from $21.5 million in the prior-year period and above the $21.93 million consensus estimate. U.S. revenue rose 7% to $14.9 million, while international revenue increased 5% to $7.9 million. Excluding China, international markets grew approximately 9% year over year.

GAAP (Generally Accepted Accounting Principles) net loss narrowed to $8.4 million, or $0.19 per share, compared with a net loss of $14.0 million, or $0.34 per share, in the same quarter last year. The result beat the consensus EPS (earnings per share) estimate of a $0.26 loss.

Gross margin was 76%, up from 75% a year earlier, while total operating expenses declined 18% to $24.9 million. Adjusted EBITDA loss narrowed to $3.5 million from $8.2 million, reflecting meaningful operating leverage. The company ended the quarter with $52.7 million in cash and cash equivalents.

Pulmonx also updated its outlook, reiterating full-year 2026 revenue guidance of $90 million to $92 million and raising its gross margin expectation to approximately 77%. Full-year operating expenses are now expected to land between $108 million and $109 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening, making it a practical resource for both retail and professional investors seeking to sharpen their research workflow.

Market Reaction and Investor Sentiment

The market responded favorably to Pulmonx's third-quarter results. According to Investing.com, shares jumped roughly 13% after the report as investors rewarded the company's return to revenue growth, the EPS beat, and the narrowed losses. Sentiment has been supported by Pulmonx's consistent record of exceeding consensus EPS estimates and by management's confirmation of full-year guidance. The addition of eight new U.S. treating centers during the quarter and the renewed China registration certificate also reinforced confidence that commercial momentum is rebuilding. Investors appeared to interpret the results as evidence that the company's restructuring and cost-reduction strategy is gaining traction.

Forward Outlook and Key Factors to Monitor

Looking ahead, several factors will shape Pulmonx's trajectory through the remainder of 2026 and into 2027. First, investors should monitor the productivity ramp of the rebuilt U.S. sales force. Management indicated that substantially all open U.S. sales positions have been filled, but average sales representative tenure remains relatively short, meaning continued execution will be central to sustaining growth.

Second, the China business represents a potential near-term catalyst. With the registration certificate renewed, Pulmonx expects to resume shipments to its distributor by early next year, which could add incremental revenue as the region comes back online.

Third, watch progress on the AeriSeal platform. Enrollment in the CONVERT2 pivotal trial continues, and management views AeriSeal as a market-expansion opportunity that could broaden the company's addressable market by roughly 20%.

Finally, keep an eye on margins and cash usage. Pulmonx now expects roughly $22 million of cash burn for full-year 2026, a 30% reduction from 2025, and raised its gross margin outlook to about 77%. Sustained operating leverage combined with renewed revenue growth will be the key test of whether the company can continue narrowing losses toward its long-term profitability goals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations